Table 1.
Clinical summary of the cohort.
| Case | Age/Gender/Race | Time before diagnosis (mo) | Clinical presentation | BSA | TNM at presentation | Treatment | Outcome | Follow up (mo) |
|---|---|---|---|---|---|---|---|---|
| 1 | 60/M/B | n/a | Plaques | 12 | T2N0M0 | XRT, IFN | AWOD | 144 |
| 2 | 82/M/W | 1 | Patch, plaque, tumors | n/a | n/a | n/a | n/a | n/a |
| 3 | 73/M/U | 12 | Plaque | 75 | T3N1M0 | MTX | n/a | n/a |
| 4 | 19/F/H | 6 | Patch, plaque | 80 | T3N0M0 | NM, TSEBT, Romi, EPOCH, Gem, UCTH1, Bendamustine, HSCT | AWOD | 46 |
| 5 | 28/M/H | 3 | Psoriasiform dermatitis | 36 | T3N0M0 | TSEBT, BXT, Romi, Liposomal doxorubicin, vorinostat, PTX, Brentuximab, CHOP, EPOCH, Gem, Denileukin Diftitox, HSCT | AWD | 168 |
| 6 | 46/F/W | 3 | Ulcerated nodule | <10 | T2N0M0 | Phototherapy, TSEBT, Liposomal doxorubicin, PTX, Brentuximab, Gem, Bendamustine, HSCT | AWD | 24 |
| 7 | 89/M/W | 12 | Psoriasiform dermatitis | >20 | T2N0M0 | ECP, Chemo | Dead | 12 |
| 8 | 78/F/H | 2 | Ulcerated plaque | 1 | T1N0M0 | XRT | AWD | n/a |
| 9 | 82/M/W | 3 | Plaques | 0.45 | T2N0M0 | Gem, Liposomal doxorubicin, BXT, NM | AWD | 18 |
| 10 | 81/M/B | 12 | Hand eczema | T3N0M0 | Gem | Dead | n/a | |
| 11 | 42/F/W | 72 | Eczema | 80 | n/a | ECP, PUVA | Dead | 36 |
| 12 | 65/M/B | (years) | Eczema | 35 | T3N0M0 | n/a | Dead | n/a |
| 13 | 87/F/W | 36 | Erythematous rash/ulcerated plaques | 30 | T3N0M0 | TSEBT, NM, BXT, Vorinostat | Dead | 15 |
| 14 | 83/M/U | 12 | Crusted/ulcerated plaques | 5 | T3N1M0 | CHOP, XRT | Dead | 7 |
| 15 | 76/M/W | 36 | Psoriasiform dermatitis | 94 | T3N0M1 | Liposomal doxorubicin, BXT, Romi, PTX | Dead | 4 |
| 16 | 85/M/U | 5 | Plaques/ulcerated tumors | 45 | T3N1M0 | None (died before able to initiate) | Dead | <1 |
| 17 | 80/F/W | 3 | Eczema/ulcerated tumors | 5 | T3N0M0 | Brentuximab, Romi, PTX | AWOD | 9 |
| 18 | 80/F/U | 11 | Psoriasiform dermatitis | 35 | T3N0M0 | TSEBT, BXT, Romi | Dead | 7 |
| 19 | 69/M/U | 120 | Patches and tumors | <5 | T3N0M1 | XRT | Dead | 24 |
| 20 | 86/M/W | 3 | Plaques and tumors | n/a | T3N0M0 | Palliative XRT, Bortezomib | Dead | n/a |
| 21 | 63/M/W | 84 | Psoriasiform dermatitis | 50 | T3N0M0 | IFN, CHOP, Phototherapy | Dead | n/a |
| 22 | 70/M/B | 10 | Spreading nodules | 80 | T3N0M0 | BXT, Denileukin Diftitox, TSEBT | Dead | 4 |
| 234 | 80/M/W | n/a | Erythematous and scaly patch | n/a | T3N0M0 | BXT, TSEBT, NM | n/a | n/a |
| 24 | 80/M/W | 1.5 | Psoriasiform dermatitis, tumors | 5 | T3N1M0 | Liposomal doxorubicin, Gem | Dead | 12 |
| 25 | 31/M/H | 24 | Necrotic ulcerations | 50 | T3N1M0 | Hyper-CVAD, BXT, PUVA, HSCT | AWD | 84 |
| 26 | 72/M/W | 5 | Ulcerated plaque, tumors | 35 | T3N0M0 | NM, phototherapy, XRT, BXT, Vorinostat, Gem, GND, CMED, Hydroxyurea, Denileukin diftitox | Dead | 72 |
| 27 | 87/M/A | 6 | Ulcerated plaques | 20 | T3N0M0 | Gem, CHOP, MTX, PTX, Liposomal doxorubicin, Romi, BXT | AWD | 12 |
| 28 | 59/F/W | 8 | Psoriasiform dermatitis | 15 | T3N0M0 | Phototherapy | AWD | 8 |
| 29 | 63/M/W | 60 | Patches, tumor | 20 | T3N0M0 | CHOEP, TSEBT, HSCT | Dead | 10 |
| 30 | 27/M/B | 18 | Psoriasiform dermatitis | 70 | T3N0M0 | MTX | AWD | n/a |
| 31 | 88/M/W | 12 | Plaques | 20 | n/a | XRT, phototherapy | AWD | 36 |
| 32 | 85/M/W | 6 | Patch, plaque, tumors | 12 | n/a | XRT, CEP | Dead | 12 |
| 33 | 21/F/W | 6 | Ulcerated plaque | n/a | T1N0M0 | EPOCH, Bendamustine, DHAP, SMILE, Gem, PTX, Romi, XRT, HSCT | AWOD | 16 |
| 34 | 86/M/W | 108 | Patches and plaques | 20 | T3N0M0 | NB-UVB, Acitretin, TSEBT | AWD | 1 |
A: Asian; AWD: alive with disease; AWOD: alive without disease; B: Black; BSA: body surface area; BXT: bexarotene; CEP: cisplatin, epirubicin, paclitaxel; CHOEP: cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone; CHOP: cyclophosphamide, adriamycin, vincristine, prednisone; CMED: cyclophosphamide, methotrexate, etoposide, dexamethasone; DHAP: dexamethasone, cytarabine, cisplatin; ECP: extracorporeal photophoresis; EPOCH: Etoposide, prednisone, Vincristine, cyclophosphamide, doxorrubicine; F: female; Gem: Gemcitabine; GND: Gemcitabine, navelbine, doxorubicin; H: Hispanic; HSCT: hematopoetic stem cell transplant; Hyper-CVAD: cyclophosphamide, vincristine, doxorubicine hydrochloride, dexamethasone; IFN: interferon; M: male; MTX: methotrexate; n\a: non-aplicable or available; NM: Nitrogen mustard; PTX: pralatexate; PUVA: psoralen ultraviolet light A; Romi: romidepsin; SMILE: dexamethasone, methotrexate, ifosfamide, l-asparaginase, etoposide; SMILE: dexamethasone, methotrexate, ifosfamide, l-asparaginase, etoposide; TSEBT: Total skin electronbeam; UCTH1: anti-human CD3; U: Unknown; XRT: radiation; W: white.